Today, a Major Shareholder at BioLife Solutions (NASDAQ: BLFS), Walter Villiger, sold shares of BLFS for $2.44M.
Following Walter Villiger’s last BLFS Sell transaction on May 25, 2017, the stock climbed by 14.7%. This is Villiger’s first Sell trade following 6 Buy transactions.
See today’s analyst top recommended stocks >>
Based on BioLife Solutions’ latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $3.81 million and quarterly net profit of $3,482. In comparison, last year the company earned revenue of $2.56 million and had a GAAP net loss of $768.2K. The Company has a Price to Book ratio of 22.8700. Currently, BioLife Solutions has an average volume of 624.9K.
Based on 3 analyst ratings, the analyst consensus is Strong Buy with an average price target of $17.67, reflecting a -4.2% downside.
The insider sentiment on BioLife Solutions has been negative according to 28 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioLife Solutions, Inc. engages in the development, manufacture, and marketing of portfolio of biopreservation tools for cells, tissues, and organs including proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media. Its products include CryoStor, BloodStor, HypoThermosol FRS, and Cell Thawing Media.
